BioMS Medical Completes Patient Recruitment In MAESTRO-01 Pivotal Phase II/III Multiple Sclerosis Trial Of MBP8298

... BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its pivotal phase II/III clinical trial of MBP8298 for the treatment of secondary progressive MS. The trial, named MAESTRO-01, will include approximately 550 patients at 48 trial sites in 10 countries. [click link for full article] ...